Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacokinetic/pharmacodynamic modeling: what it is!

W A Colburn1

  • 1Warner-Lambert/Parke-Davis Pharmaceutical Research, Pharmacokinetics/Drug Metabolism Department, Ann Arbor, Michigan 48105.

Journal of Pharmacokinetics and Biopharmaceutics
|October 1, 1987
PubMed
Summary

Pharmacokinetic/pharmacodynamic (PK/PD) modeling, though established, requires economic incentives for broader application. Such investment promises scientific advancement and streamlined drug approvals, potentially reducing the drug lag.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thalidomide dose proportionality assessment following single doses to healthy subjects.

Journal of clinical pharmacology·2001
Same author

Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Journal of clinical pharmacology·2001
Same author

Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.

Journal of clinical pharmacology·2001
Same author

Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin.

Anesthesia and analgesia·2001
Same author

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.

Biopharmaceutics & drug disposition·2000
Same author

An evolution of drug development and clinical pharmacology during the 20th century.

Journal of clinical pharmacology·2000

Area of Science:

  • Pharmacology
  • Drug Development
  • Regulatory Science

Background:

  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling is a powerful tool in drug development.
  • Despite decades of use, PK/PD modeling is not yet fully realized in its potential applications.

Purpose of the Study:

  • To highlight the need for economic incentives to advance PK/PD modeling.
  • To explore the potential of PK/PD modeling to improve drug development efficiency and regulatory processes.

Main Methods:

  • The abstract does not specify methods but discusses the application and future of PK/PD modeling.
  • Focuses on the economic and regulatory aspects influencing the adoption of PK/PD modeling.

Main Results:

  • Increased investment in PK/PD modeling is crucial for its development and application.
  • Economic incentives from agencies like the NIH and FDA are proposed to encourage scientists.

Conclusions:

  • Advancing PK/PD modeling through incentives can lead to better scientific understanding of concentration-effect relationships.
  • This advancement may result in more efficient and acceptable New Drug Applications (NDAs), potentially addressing the 'drug lag'.

Related Experiment Videos